Drug Signifor for Cushing's Disease

European Union regulators approved Novartis drug Signifor as a treatment for Cushing's disease.

The group said it was the first time the EU has approved a drug to treat the rare disease, which is caused by a tumour or growth on the pituitary gland and is generally treated surgically.

Adreno Cortical Carcinoma - Symptoms-Diagnosis-Treatment-Prognosis
Adrenocortical carcinoma is a rare but aggressive form of cancer that affects the outer cortex layer of the adrenals situated atop the kidneys.

"The European Commission has approved Signifor (pasireotide) for the treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed," Novartis said in a statement.

Cushing's disease causes fatigue, depression, high blood pressure, upper-body obesity and a reddened moon face.

The approval follows phase-three clinical trials that found Cushing's patients who received two daily injections of Signifor for six months had reduced levels of cortisol, a stress hormone present in above-normal quantities in people with the disease.

Experimental Drug Proves Effective Against Cushing's Disease
New investigational drug pasireotide lowers urinary cortisol levels and improves symptoms of Cushing's disease, shows clinical trial study.

Cushing's affects between one and two people per million each year.

Analysts at Zurich state-owned bank ZKB estimated 20,000 European patients could be treated with Signifor, generating potential sales of some $700 million (529.3 million euros) for Novartis over five years.

Adrenalectomy Can Help In Ameliorating Cushing Syndrome
Patients with a mild form of Cushing syndrome, a metabolic disorder caused by adrenal tumors, demonstrate substantial clinical improvement after adrenalectomy.

Source-AFP

Adrenalectomy may Help Patients With Mild Cushing Syndrome
A new study has found that patients with a mild form of Cushing syndrome show considerable clinical improvement after adrenalectomy.